PRESS RELEASE: Successfully Seeding a Broken Heart – Heartseed Inc. succeeds in first human dosing of cardiomyocyte spheroids derived from allogeneic iPS Cells in PhⅠ/Ⅱ clinical trial for advanced heart failure utilizing iMatrix™ family of products. Heartseed Inc, announced that Heartseed successfully dosed the first patient with HS-001, an investigational iPS cell derived therapy for […]
Iwai North America Inc. executed a distributor’s agreement with Cell Science & Technology Institute Inc. (CSTI). CSTI is known for their quality culture medium for the Immuno-therapy and stem cells. The addition of these culture media to Iwai’s current product line up, creates a synergy among the products, thus providing researches reliable quality products for […]
Iwai North America Inc. executed a marketing collaboration agreement with Zenogen Pharma. Zenogen Pharma is known for their cryopreservation medium, CELLBANKER®. With over 80% cell viability for most cell lines along with +10 years of viability data, it is one of the trusted cryopreservation medium on the market.